Walgreens stock dives after Goldman downgrade on concerns about core business
Goldman’s new stock price target is about 14% below Friday’s trading level
All Posts in "Markets"
Gold declines as palladium retreats from a record settlement
Gold futures trade lower week to date
Are FAANG stocks poised to re-assert market leadership?
Highflying tech stocks have taken a beating since September, but some investors argue that’s about to end
GE shares surge 12% premarket on news of new IoT business, JPMorgan upgrade
General Electric Co. GE, -0.42% said Thursday it is launching a $1.2 billion industrial internet-of-things software company, which will be wholly owned by independently run with its own board of directors. The company will bring together GE Digital’s IIoT products, and the GE Power Digital and Grid Software Solutions businesses, the company said in a statement.
U.S. budget deficit jumps to $205 billion in November
CBO publishes list of 121 ways to cut the deficit
U.S. stock futures point to modest gains as trade concerns dominate
Jobless claims fall
Think it’s cheaper to shop online? Think again
4 reasons online shopping costs you more
The likelihood of a bitcoin bounce is diminishing, says analyst
Altcoins slip further, drags crypto market value to $108 billion
Oil ends lower as U.S. crude supplies post smaller-than-expected decline
EIA data show weekly U.S. crude stockpiles down 1.2 mln barrels
Stitch Fix shares sink 26% as focus shifts from new clients to selling more to existing ones
Stitch Fix’s shares plummet as investors question the company’s change in strategy
Biopharma VC hit highest quarterly level since 2022, but challenges in exit landscape remain
Ex-GSK CEO takes up board post at aging and obesity biotech BioAge
After $213M round, gene editing biotech Tome shrinks operations as investor sentiment worsens
Novartis, Versant hope to repeat Chinook’s success by arming kidney biotech Borealis with $150M
Roche ramps up lab testing capacity for mpox worldwide following WHO declaration
BioMarin creates new-look R&D and deal teams with Roche’s Sabry, Amgen’s Friberg
FDA rejects Regeneron’s blood cancer bispecific, delaying would-be challenger to J&J and Pfizer
Researchers receive $6.9M grant for tau-targeting drug with potential in Alzheimer’s and beyond
BridgeBio launches another offshoot with $300M and early genetic disease programs
PreciseDx picks up $20.7M to advance AI-based breast cancer risk assessment